Skip to content

KLINIFARM

Active Private limited companyfounded 1988active for 38 yearsKiezelstraat 121, 3500 HasseltKBO/BCE: BE 0434.190.014 #2 oldest company in Limburg, Research and development sector

Lifetime

20 annual accounts with figures on one time axis, 38 filings since 1989
peak of €147,220 in 2023
-€1,493▲ €6,098
lowest -€46,709 in 2025
-€44,856▲ €1,854
peak of €637,374 in 2024
€400,612▼ 24.5%
€86,723▲ 44.0%
Board2 names since 1988
2 directors and 1 other
Documentsfilings and deeds
24-09-202637 days before the deadline
2026micro format
Gross margin from -€7,591 to -€1,493Loss of €44,856Dividend €85,237Equity from €530,704 to €400,612Debts from €60,222 to €86,723Cash from €42,151 to €3,733

Key points

from the 2026 annual accounts

Equity

€400,612 ▼ 24.5%
530,7042025-44,856Loss-85,237Dividend400,6122026

KLINIFARM paid out €85,237 in dividends in a year with a loss of €44,856.

Losses

-€91,565 in two years
-46,7092025-44,8562026

The 2025 and 2026 financial years closed with a loss. 2025 was the heaviest.

Filings

38 annual accounts since 1989
deadline1990200020102020

The 2018 accounts came 30 days late. The other nine of the last ten were filed on time.

Turnover not published in the abbreviated or micro format

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 8,616 companies had the same profile as KLINIFARM has now. Each dot stands for 22 companies, two years later.

94.2%
were still trading
5.2%
stopped another way
0.5%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a small loss

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,894 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 8,616 companies, not a prediction for KLINIFARM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager
Director
  • deed of 24-03-2014
  • deed of 24-03-2014
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0434190014
. appointed as statutory director Gazette deed
Capital increase of €263,560.09 to €282,400 The capital rose from €18,839.91 to €282,400 · appointed as statutory manager · Gazette deed
First establishment Kiezelstraat 121, Hasselt
All 49 events

Comparable companies

same main activity, similar in size and age
Company
KLINIFARM Hasselt €0.5m -€1,493 82.2% -
Airlines International Representation in Europe Etterbeek €0.6m -€147,294 75.5% -
StabilisersPlus Etterbeek €0.2m -€130,328 85.5% -
INSTITUT DE SECURITE INCENDIE - INSTITUUT VOOR BRANDVEILIGING Liège €0.3m €6,484 62.9% -
SHANT LABORATORIES BELGIUM Tubize €1.1m €3,404 -38.2% -
INBIOVERITAS Schilde €0.2m -€74,831 -60.1% 0
RESEARCH LINK Thuin €0.5m €4,798 55.3% -

These companies have the same main activity as KLINIFARM: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €189,000 and €1.1m, founded between 1983 and 2003.

Official details

Source: KBO
Status
Active since 29-04-1988Normal situation
Activity
Other research and development on natural sciencesNACE 72109
Establishment unit
2.038.876.9493500 Hasselt, since 28-06-1988
Financial year end
31 March
Peppol
Reachable since 17-07-2026
Company details

Annual accounts to 31-03-2026

€487,335▼ 17.5%
Filing
Filed on 24-09-2026, 37 days before the end of the filing period
Financials

Insights on KLINIFARM

KLINIFARM files the micro format. That format states no turnover. The gross margin fell from €51,328 in 2007 to -€1,493 in 2026.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about KLINIFARM

What is the company number of KLINIFARM?
The company number of KLINIFARM is 0434.190.014. The VAT number is the same number with BE in front: BE 0434.190.014.
Where is KLINIFARM based?
The registered office is at Kiezelstraat 121, 3500 Hasselt.Company details
What does KLINIFARM do?
According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
What is the legal form of KLINIFARM?
KLINIFARM is a private limited company (BV).
When was KLINIFARM founded?
KLINIFARM was founded on 29-04-1988.
Is KLINIFARM still active?
Yes, KLINIFARM is an active enterprise in the KBO register.
What is the turnover of KLINIFARM?
The annual accounts for financial year 2026 state no turnover. The abbreviated or micro format does not require it.Financials
Is KLINIFARM profitable?
In financial year 2026, KLINIFARM made a loss of €44,856.
Where can I find the annual accounts of KLINIFARM?
KLINIFARM filed 38 annual accounts with the National Bank of Belgium, the latest for financial year 2026.
When are the next annual accounts of KLINIFARM due?
KLINIFARM must file the annual accounts for financial year 2027 by 31-10-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.